San Diego-centered Viking Therapeutics marked itself as a serious competitor during the weight loss drug current market in February following revealing promising data from a mid-phase demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection and in March the company u